Adelphi supports Oxbridge Biotech Roundtable consulting case competition
On Saturday 31st March, Adelphi supported a National University healthcare consulting competition which took place at Manchester Business School.
Teams of post-grads, post-docs and MBAs from across the UK were invited to compete against each other and deliver a presentation to a hypothetical big-pharma client, represented by a panel of industry experts. Acting as consulting firms, the teams provided recommendations on how to replenish its diminishing pipeline to diversify their development opportunities in diabetes through the in-licensing/acquisition of technology from one of three hypothetical biotech companies.
Nick Proctor (Adelphi Access) was one of the judges on the day and said ‘the standard of presentations was very high, with all participants embracing the challenges in the pharma industry and providing some great ideas’. ‘It was great to be able to share some of our knowledge with people who I have no doubt will be future leaders in healthcare’
Nick also ran a seminar on how to present healthcare consulting findings, and participated in a panel discussion, entitled “The marriage of pharma and biotech“, discussing biotech/pharma partnering for drug development, whilst Jane Neale (Adelphi Access) provided mentoring for teams as they worked on their presentations.
At the end of the day the winning team was presented with a £1000 prize from OBR.
Oxford Biotech Roundtable (OBR) is a professional organisation that enables an on-campus conversation between academia and industry to move ideas forward. They do this via education, communication outreach, strategy consulting, and fostering entrepreneurship. For more information on OBR, please visit: www.oxbridgebiotech.com
Adelphi was founded in 1986, substantially expanding its reach and services in 1998 by becoming part of the USA-Headquartered, Omnicom Corporation. For over twenty five years Adelphi has successfully supported the development, launch and marketing of pharmaceutical brands in most therapeutic areas.